📰 Archives & Recherche

🇺🇸 États-Unis • Santé

🔍 Rechercher dans les archives

📊 2,308 articles archivé(s)
Page 82 / 116
Judge blocks US government from slimming down vaccine recommendations

Judge blocks US government from slimming down vaccine recommendations

A federal judge in Boston has blocked federal health officials from cutting the number of vaccines recommended for every child, and says U.S. Health S...

Judge blocks US government from slimming down vaccine recommendations - AP News

Judge blocks US government from slimming down vaccine recommendations AP NewsJudge Strikes Down RFK Jr.’s Vaccine Policies in Blow to Trump’s Heal...

Judge blocks federal health officials’ changes to childhood vaccine recommendations

Judge blocks federal health officials’ changes to childhood vaccine recommendations....

First known case of severe mpox virus strain detected in NYC - New York Post

First known case of severe mpox virus strain detected in NYC New York PostFirst known case of severe Mpox strain discovered in New York City ABC7 New ...

Immunome (IMNM) Expected to Announce Earnings on Wednesday

Immunome (IMNM) Expected to Announce Earnings on Wednesday

Immunome (NASDAQ:IMNM – Get Free Report) will likely be posting its Q4 2025 results before the market opens on Wednesday, March 18th. Analysts expec...

Wellgistics Health, Inc. (NASDAQ:WGRX) Sees Large Increase in Short Interest

Wellgistics Health, Inc. (NASDAQ:WGRX) Sees Large Increase in Short Interest

Wellgistics Health, Inc. (NASDAQ:WGRX – Get Free Report) was the target of a large growth in short interest in February. As of February 27th, there ...

Keona Health: Fragmented Patient Access Systems Drive No-Shows and Missed Calls

Keona Health: Fragmented Patient Access Systems Drive No-Shows and Missed Calls

Disconnected Scheduling Are Costing Healthcare Organizations Patients — Keona Health Shows How to Fix the Gaps Chapel...

Problematic social media use predicts higher depressive symptoms in adolescents under 16

Problematic social media use predicts higher depressive symptoms in adolescents under 16

Problematic use of social media—characterized by loss of control and compulsive engagement—may significantly increase depressive symptoms in adole...

Walk More to Stress Less: Get Moving to Improve Well-Being

Walk More to Stress Less: Get Moving to Improve Well-Being

...

Walk More to Stress Less: Get Moving to Improve Well-Being

Walk More to Stress Less: Get Moving to Improve Well-Being

...

Walk More to Stress Less: Get Moving to Improve Well-Being

Walk More to Stress Less: Get Moving to Improve Well-Being

...

Walk More to Stress Less: Get Moving to Improve Well-Being

Walk More to Stress Less: Get Moving to Improve Well-Being

...

Walk More to Stress Less: Get Moving to Improve Well-Being

Walk More to Stress Less: Get Moving to Improve Well-Being

...

Vitamin B2 Pathway Identified as Potential Target for Cancer Therapy

Vitamin B2 Pathway Identified as Potential Target for Cancer Therapy

Vitamin B2 metabolism helps cancer cells resist ferroptosis, a form of programmed cell death. Targeting riboflavin-related pathways with compounds lik...

'Those of you who look like me': Director says Oscar opened doors for Koreans, despite previous wins

'Those of you who look like me': Director says Oscar opened doors for Koreans, despite previous wins

When "KPop Demon Hunters" won the Academy Award for best animated feature film, the director falsely claimed the film's victory was the first such ins...

Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance

Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance

HONG KONG, March 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispec...

Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance

HONG KONG, March 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispec...

Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance

Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance

HONG KONG, March 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispec...

Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance

Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance

HONG KONG, March 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispec...

Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance

Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance

HONG KONG, March 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispec...